2020
Exome Sequencing Reveals Common and Rare Variants in F5 Associated With ACE Inhibitor and Angiotensin Receptor Blocker–Induced Angioedema
Maroteau C, Siddiqui M, Veluchamy A, Carr F, White M, Cassidy AJ, Baranova EV, Rasmussen ER, Eriksson N, Bloch KM, Brown NJ, Bygum A, Hallberg P, Karawajczyk M, Magnusson PKE, Yue Q, Syvänen A, von Buchwald C, Alfirevic A, der Zee A, Wadelius M, Palmer CNA, PREDICTION‐ADR. Exome Sequencing Reveals Common and Rare Variants in F5 Associated With ACE Inhibitor and Angiotensin Receptor Blocker–Induced Angioedema. Clinical Pharmacology & Therapeutics 2020, 108: 1195-1202. PMID: 32496628, PMCID: PMC10306231, DOI: 10.1002/cpt.1927.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioedemaAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsCase-Control StudiesDNA Mutational AnalysisEuropeExomeExome SequencingFactor VFemaleGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansMaleMiddle AgedMutation RateMutation, MissenseRisk AssessmentRisk FactorsUnited StatesConceptsAngiotensin receptor blockersACEi-AEReceptor blockersLife-threatening adverse reactionsMissense variantsRare variantsCommon variantsRare missense variantsGene risk scoreACE inhibitorsAdverse reactionsDeleterious missense variantsHigh riskRisk scoreAngioedemaEnzyme inhibitorsNeck regionExome sequencingAsian populationsDifferent centersBlood clottingBlockersF5 geneRiskInhibitors
2018
Endogenous bradykinin and B1-B5 during angiotensin-converting enzyme inhibitor–associated angioedema
Hubers S, Kohm K, Wei S, Yu C, Nian H, Grabert R, Sexton DJ, Brown NJ. Endogenous bradykinin and B1-B5 during angiotensin-converting enzyme inhibitor–associated angioedema. Journal Of Allergy And Clinical Immunology 2018, 142: 1636-1639.e5. PMID: 30036596, PMCID: PMC6226317, DOI: 10.1016/j.jaci.2018.06.037.Peer-Reviewed Original Research
2017
Angiotensin-converting Enzyme Inhibitor and Other Drug-associated Angioedema
Stone C, Brown NJ. Angiotensin-converting Enzyme Inhibitor and Other Drug-associated Angioedema. Immunology And Allergy Clinics Of North America 2017, 37: 483-495. PMID: 28687104, DOI: 10.1016/j.iac.2017.04.006.Peer-Reviewed Original ResearchConceptsDrug-induced angioedemaEnzyme inhibitorsAngiotensin-converting enzyme inhibitorNon-β-lactam antibioticsNonsteroidal antiinflammatory agentsNonallergic angioedemaSubstance PTherapeutic decisionsAngioedemaAntiinflammatory agentsLactam antibioticsOther DrugΒ-lactam antibioticsDrugsPatientsLeukotrienesBradykininGenetic variantsAntibioticsInhibitorsAngiotensinProstaglandinsAgentsHistamineMainstay
2016
Effect of bradykinin receptor antagonism on ACE inhibitor-associated angioedema
Straka BT, Ramirez CE, Byrd JB, Stone E, Woodard-Grice A, Nian H, Yu C, Banerji A, Brown NJ. Effect of bradykinin receptor antagonism on ACE inhibitor-associated angioedema. Journal Of Allergy And Clinical Immunology 2016, 140: 242-248.e2. PMID: 27913306, PMCID: PMC5705179, DOI: 10.1016/j.jaci.2016.09.051.Peer-Reviewed Original ResearchConceptsACE inhibitor-associated angioedemaResolution of symptomsVisual analog scaleAnalog scaleReceptor antagonistTreatment groupsBradykinin BEnzyme (ACE) inhibitor-associated angioedemaStudy drug administrationReceptor antagonist icatibantHours of presentationTreatment of attacksC1 inhibitor deficiencyBradykinin receptor antagonismFrequency of administrationVanderbilt University Medical CenterUniversity Medical CenterMassachusetts General HospitalTwo-thirdsAntagonist icatibantBowel edemaWhite patientsH2 blockersClinical efficacyInhibitor deficiencyCombined Angiotensin Receptor Antagonism and Neprilysin Inhibition
Hubers SA, Brown NJ. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition. Circulation 2016, 133: 1115-1124. PMID: 26976916, PMCID: PMC4800749, DOI: 10.1161/circulationaha.115.018622.Peer-Reviewed Original ResearchMeSH KeywordsAbnormalities, Drug-InducedAminobutyratesAngioedemaAngiotensin Receptor AntagonistsBiphenyl CompoundsBradykininContraindicationsDrug CombinationsDrug CostsDrug SynergismEnalaprilEnzyme InhibitorsFemaleFollow-Up StudiesHeart FailureHumansHyperkalemiaHypertensionKidneyMulticenter Studies as TopicNatriuretic PeptidesNeprilysinPregnancyProdrugsProspective StudiesPyridinesRandomized Controlled Trials as TopicStroke VolumeTetrazolesThiazepinesValsartanConceptsValsartan/sacubitrilReduced ejection fractionHeart failureNatriuretic peptideEjection fractionN-terminal pro-brain natriuretic peptideNeprilysin inhibitor prodrug sacubitrilPro-brain natriuretic peptideAngiotensin receptor blocker valsartanAngiotensin receptor antagonismAngiotensin receptor blockersHeart Failure TrialReceptor blocker valsartanAngiotensin receptor antagonistsBrain natriuretic peptideOngoing clinical trialsMechanism of actionNeprilysin inhibitionAldosterone antagonistsAldosterone systemReceptor blockersBlood pressureFailure TrialPathophysiological mechanismsReceptor antagonism
2013
Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema
Pare G, Kubo M, Byrd JB, McCarty CA, Woodard-Grice A, Teo KK, Anand SS, Zuvich RL, Bradford Y, Ross S, Nakamura Y, Ritchie M, Brown NJ. Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema. Pharmacogenetics And Genomics 2013, 23: 470-478. PMID: 23838604, PMCID: PMC3904664, DOI: 10.1097/fpc.0b013e328363c137.Peer-Reviewed Original ResearchMeSH KeywordsAngioedemaAngiotensin-Converting Enzyme InhibitorsBenzimidazolesBenzoatesBlack or African AmericanDouble-Blind MethodDrug Therapy, CombinationGenome-Wide Association StudyHumansIsoenzymesNeprilysinPolymorphism, Single NucleotideProtein Kinase CProtein Kinase C-thetaProto-Oncogene Proteins c-etsRamiprilRepressor ProteinsTelmisartanWhite PeoplePollen Count and Presentation of Angiotensin-Converting Enzyme Inhibitor–Associated Angioedema
Straka B, Nian H, Sloan C, Byrd JB, Woodard-Grice A, Yu C, Stone E, Steven G, Hartert T, Teo KK, Pare G, McCarty CA, Brown NJ. Pollen Count and Presentation of Angiotensin-Converting Enzyme Inhibitor–Associated Angioedema. The Journal Of Allergy And Clinical Immunology In Practice 2013, 1: 468-473.e4. PMID: 24565618, PMCID: PMC4042396, DOI: 10.1016/j.jaip.2013.05.003.Peer-Reviewed Original ResearchConceptsACE inhibitor-associated angioedemaRate of angioedemaSeasonal allergiesRamipril Global Endpoint TrialAngiotensin converting enzyme (ACE) inhibitorsEnzyme (ACE) inhibitor-associated angioedemaIncidence of angiotensinMonths of presentationAdverse drug eventsDate of presentationVanderbilt University Medical CenterUniversity Medical CenterMarshfield Clinic Personalized Medicine Research ProjectOngoing TelmisartanEndpoint trialsACE inhibitorsPollen countsDrug eventsAssociated angioedemaObservational studyCohort analysisMedical CenterHospital settingAngioedemaPersonalized Medicine Research Project
2010
Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema
Woodard-Grice AV, Lucisano AC, Byrd JB, Stone ER, Simmons WH, Brown NJ. Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema. Pharmacogenetics And Genomics 2010, 20: 532-536. PMID: 20625347, PMCID: PMC2945219, DOI: 10.1097/fpc.0b013e32833d3acb.Peer-Reviewed Original ResearchAssociation of angiotensin‐converting enzyme inhibitor‐associated angioedema with transplant and immunosuppressant use
Byrd JB, Woodard‐Grice A, Stone E, Lucisano A, Schaefer H, Yu C, Eyler AE, Salloum NE, Brown NJ. Association of angiotensin‐converting enzyme inhibitor‐associated angioedema with transplant and immunosuppressant use. Allergy 2010, 65: 1381-1387. PMID: 20557296, PMCID: PMC3305268, DOI: 10.1111/j.1398-9995.2010.02398.x.Peer-Reviewed Original ResearchConceptsACE inhibitor-associated angioedemaEnzyme (ACE) inhibitor-associated angioedemaTransplant patientsImmunosuppressant useDipeptidyl peptidase IV activityPeptidase IV activityTransplant statusDPPIV activityCardiac transplant patientsRenal transplant patientsChronic renal failureAssociation of angiotensinEffects of immunosuppressantsIncidence of angioedemaActivity of DPPIVCardiac transplantImmunosuppressant therapyRenal failureConsecutive patientsACE inhibitorsImmunosuppressant agentsAngioedema casesUnivariate analysisAngioedemaSeasonal allergies
2009
Dipeptidyl Peptidase-IV Inhibitor Use Associated With Increased Risk of ACE Inhibitor-Associated Angioedema
Brown NJ, Byiers S, Carr D, Maldonado M, Warner BA. Dipeptidyl Peptidase-IV Inhibitor Use Associated With Increased Risk of ACE Inhibitor-Associated Angioedema. Hypertension 2009, 54: 516-523. PMID: 19581505, PMCID: PMC2758288, DOI: 10.1161/hypertensionaha.109.134197.Peer-Reviewed Original ResearchConceptsACE inhibitorsRisk of angioedemaVildagliptin useDPP-IV inhibitorsComparator-treated patientsEnzyme (ACE) inhibitor-associated angioedemaStudy drug exposureAngiotensin receptor blockersPhase III studyPossible drug-drug interactionsIncidence of angioedemaCase report formsDipeptidyl peptidase IV inhibitorsDrug-drug interactionsDPP-IV inhibitor vildagliptinPathogenesis of angiotensinPeptidase IV inhibitorsAngioedema riskClinical angioedemaReceptor blockersIII studyAbsolute riskAdjudication committeeDPP-IV inhibitionDrug exposure
2007
Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor–Associated Angioedema
Byrd JB, Touzin K, Sile S, Gainer JV, Yu C, Nadeau J, Adam A, Brown NJ. Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor–Associated Angioedema. Hypertension 2007, 51: 141-147. PMID: 18025295, PMCID: PMC2749928, DOI: 10.1161/hypertensionaha.107.096552.Peer-Reviewed Original ResearchConceptsEnzyme (ACE) inhibitor-associated angioedemaDipeptidyl peptidase IV activityHistory of angiotensinPeptidase IV activityControl subjectsSubstance PDipeptidyl peptidase IVEnzyme inhibitorsLife-threatening adverse effectsAngiotensin converting enzyme (ACE) inhibitorsEnzyme inhibitionAbsence of angiotensinPrevalence of smokingSera of patientsCase-control studyPeptidase IVSubstrates of angiotensinTissue edemaAssociated angioedemaAminopeptidase P activityVascular permeabilityAngioedemaAngiotensinAminopeptidase N activityAmino-terminal degradation
2006
Angiotensin-Converting Enzyme Inhibitor-Associated Angioedema
Byrd JB, Adam A, Brown NJ. Angiotensin-Converting Enzyme Inhibitor-Associated Angioedema. Immunology And Allergy Clinics Of North America 2006, 26: 725-737. PMID: 17085287, DOI: 10.1016/j.iac.2006.08.001.Peer-Reviewed Original ResearchConceptsACE inhibitor-associated angioedemaAngiotensin converting enzyme (ACE) inhibitorsEnzyme inhibitor usersNon-ACE pathwaysInhibitor usersAdverse eventsClinical recognitionSubstance PAssociated angioedemaEnzyme inhibitorsAngioedemaDefective degradationNonsmokersAngiotensinSmokersPathogenesisWhite AmericansBradykininIncidence
2005
The Kallikrein-Kinin System: Current and Future Pharmacological Targets
Moreau ME, Garbacki N, Molinaro G, Brown NJ, Marceau F, Adam A. The Kallikrein-Kinin System: Current and Future Pharmacological Targets. Journal Of Pharmacological Sciences 2005, 99: 6-38. PMID: 16177542, DOI: 10.1254/jphs.srj05001x.Peer-Reviewed Original ResearchMeSH KeywordsAngioedemaAngiotensin-Converting Enzyme InhibitorsAnimalsAprotininBradykininBradykinin B2 Receptor AntagonistsCardiovascular DiseasesComplement C1 Inactivator ProteinsComplement C1 Inhibitor ProteinHumansInflammationKallikrein-Kinin SystemKallikreinsKidney DiseasesKininsNeprilysinPeptidyl-Dipeptidase APolymorphism, GeneticPyridinesRandomized Controlled Trials as TopicReceptor, Bradykinin B1Receptor, Bradykinin B2SerpinsThiazepinesConceptsKallikrein-kinin systemMultiple pharmacological interventionsPrecursors of kininsFuture pharmacological targetsProinflammatory effectsVasoactive kininsPharmacological interventionsCardiovascular propertiesPharmacological targetsComplement pathwayKininsActive kininsPathological processesPharmacological activitiesPlasma kallikreinMetabolic cascadeImportant metabolic pathwaysMetabolic pathwaysAntiproteasesA Variant in XPNPEP2 Is Associated with Angioedema Induced by Angiotensin I–Converting Enzyme Inhibitors
Duan QL, Nikpoor B, Dubé M, Molinaro G, Meijer IA, Dion P, Rochefort D, Saint-Onge J, Flury L, Brown NJ, Gainer JV, Rouleau JL, Agostoni A, Cugno M, Simon P, Clavel P, Potier J, Wehbe B, Benarbia S, Marc-Aurèle J, Chanard J, Foroud T, Adam A, Rouleau GA. A Variant in XPNPEP2 Is Associated with Angioedema Induced by Angiotensin I–Converting Enzyme Inhibitors. American Journal Of Human Genetics 2005, 77: 617-626. PMID: 16175507, PMCID: PMC1275610, DOI: 10.1086/496899.Peer-Reviewed Original Research
2002
Dipeptidyl Peptidase IV Activity in Patients With ACE-Inhibitor-Associated Angioedema
Lefebvre J, Murphey LJ, Hartert TV, Jiao Shan R, Simmons WH, Brown NJ. Dipeptidyl Peptidase IV Activity in Patients With ACE-Inhibitor-Associated Angioedema. Hypertension 2002, 39: 460-464. PMID: 11882590, DOI: 10.1161/hy0202.103054.Peer-Reviewed Original ResearchConceptsDPPIV activityHypertensive volunteersHypertensive subjectsRemote historyAcute ACE inhibitionSerum DPPIV activityUntreated hypertensive controlsUntreated hypertensive subjectsMetabolism of bradykininDipeptidyl peptidase IV activityAcute ACEIChronic ACEiPeptidase IV activityCorticosteroid treatmentHypertensive controlsHypertensive patientsNormotensive volunteersNormotensive controlsACE inhibitorsACE inhibitionSubstance PBradykinin degradationAssociated angioedemaACEIAngioedema
1999
Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema
Blais C, Rouleau J, Brown N, Lepage Y, Spence D, Munoz C, Friborg J, Geadah D, Gervais N, Adam A. Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema. Immunopharmacology 1999, 43: 293-302. PMID: 10596866, DOI: 10.1016/s0162-3109(99)00133-2.Peer-Reviewed Original ResearchConceptsDes-Arg9AE patientsC subjectsLife-threatening adverse reactionsEnzyme (ACE) inhibitor-associated angioedemaMetabolism of bradykininLocal inflammatory reactionEnzyme defectPreincubation of seraBK metabolismSensitive enzyme immunoassayB1 agonistSerum metabolismAdverse reactionsControl subjectsInflammatory reactionACEIAngioedemaAbnormal metabolismPatientsEnzyme inhibitorsSynthetic bradykininControl seraBradykininEnzyme immunoassay
1997
Recurrent Angiotensin-Converting Enzyme Inhibitor—Associated Angioedema
Brown N, Snowden M, Griffin M. Recurrent Angiotensin-Converting Enzyme Inhibitor—Associated Angioedema. JAMA 1997, 278: 232-233. DOI: 10.1001/jama.1997.03550030072037.Peer-Reviewed Original ResearchConceptsACE inhibitor useAngiotensin converting enzyme (ACE) inhibitorsACE inhibitorsInhibitor useRecurrent angioedemaEnzyme inhibitorsEpisodes of angioedemaRate of angioedemaRetrospective cohort studyDiagnosis of angioedemaRisk of angioedemaTennessee Medicaid programAngioedema recurrencesCohort studySerious morbidityRecurrent episodesMedical recordsAssociated angioedemaMultiple recurrencesMedicaid enrolleesAngioedemaPatientsRecurrenceNumber of causesMedicaid programRecurrent angiotensin-converting enzyme inhibitor--associated angioedema.
Brown N, Snowden M, Griffin M. Recurrent angiotensin-converting enzyme inhibitor--associated angioedema. JAMA 1997, 278: 232-3. PMID: 9218671, DOI: 10.1001/jama.278.3.232.Peer-Reviewed Original ResearchConceptsACE inhibitor useACE inhibitorsInhibitor useRecurrent angioedemaEnzyme inhibitorsAngiotensin-converting enzyme inhibitorEpisodes of angioedemaRate of angioedemaRetrospective cohort studyDiagnosis of angioedemaRisk of angioedemaTennessee Medicaid programAngioedema recurrencesCohort studySerious morbidityRecurrent episodesMedical recordsAssociated angioedemaMultiple recurrencesMedicaid enrolleesAngioedemaPatientsRecurrenceNumber of causesMedicaid program
1996
Increased sensitivity to bradykinin among African Americans
Gainer J, Nadeau J, Ryder D, Brown N. Increased sensitivity to bradykinin among African Americans. Journal Of Allergy And Clinical Immunology 1996, 98: 283-287. PMID: 8757204, DOI: 10.1016/s0091-6749(96)70151-3.Peer-Reviewed Original ResearchConceptsKallikrein-kinin systemWheal responseAfrican AmericansLife-threatening side effectsTissue kallikrein-kinin systemACE inhibitor-associated angioedemaACE inhibitor doseMechanisms of angioedemaDouble-blind fashionDoses of bradykininAfrican American raceNormotensive African AmericansUrinary kallikrein levelsACE inhibitor-induced increaseInhibitor-induced increaseBradykinin doseConcurrent medicationsEssential hypertensionKallikrein levelsBradykinin levelsExogenous bradykininIntradermal injectionAmerican raceSide effectsInhibitor doseBlack Americans have an increased rate of angiotensin converting enzyme inhibitor‐associated angioedema
Brown N, Ray W, Snowden M, Griffin M. Black Americans have an increased rate of angiotensin converting enzyme inhibitor‐associated angioedema. Clinical Pharmacology & Therapeutics 1996, 60: 8-13. PMID: 8689816, DOI: 10.1016/s0009-9236(96)90161-7.Peer-Reviewed Original ResearchConceptsACE inhibitor useEnzyme (ACE) inhibitor-associated angioedemaInhibitor useACE inhibitorsRelative riskWhite subjectsACE inhibitor-associated angioedemaACE inhibitor doseRate of angiotensinRetrospective cohort studyRisk of angioedemaTennessee Medicaid programAssociation of racePotential confounding factorsEffect of doseSpecific ACE inhibitorDiuretic useCohort studyConcurrent medicationsPatient characteristicsPrevious hospitalizationAngioedemaInhibitor doseConfounding factorsYears of use